- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04421352
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
March 6, 2024 updated by: CStone Pharmaceuticals
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors
A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients
Study Overview
Detailed Description
This is a dose-escalation study of Low-dose Radiation in combination with CS1001 in relapsed SCLC patients.
Patients are assigned to 3 treatment groups received from 3 Gy to 15Gy, to determine the safety, tolerability and the maximal tolerant dose.
Biomarkers and immunological markers are collected and analyzed as well.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sichuan
-
Chendu, Sichuan, China, 610041
- West China Hospital, Sichuan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with histologically or cytologically confirmed LS-SCLC or ES-SCLC and experienced progression since first-line standard platinum containing dual-drug chemotherapy.
- Patients whose initial diagnosis was limited must undergo radical chest radiotherapy and the time of tumor progression is not less than 3 months from the end of radiotherapy, or cannot receive radical chest radiotherapy due to specific reasons
- At least one extracranial measurable lesion (RECIST v1.1), and for a lesion that has received radiotherapy, progression of the lesion after radiotherapy must be confirmed.
- Patients with brain metastases are allowed to receive previous radiotherapy and their condition is stable, but the time to the end of radiotherapy must not be less than 3 months.
- No radiotherapy contraindications were judged by the radiologist
- ECOG performance status of 0 or 1.
- Patients with life expectancy ≥ 3 months.
- Patients must have adequate organ function.
- Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 6 months after last study drug administration.
Exclusion Criteria:
- Subjects known to have primary CNS tumors or meningeal metastases or unstable CNS metastases.
- Patients with active autoimmune diseases or history of autoimmune diseases should be excluded.
- Patients who have received immune checkpoint proteins/antibody/medicine (including PD-1, PD-L1, etc) for treatment.
- Known history of HIV infection.
- Subjects with active chronic hepatitis B or active hepatitis C .
- Patients who have serious hypersensitive reaction to monoclonal antibodies, and have history of uncontrolled allergic asthma.
- Known history of alcoholism or drugs abuse.
- Subjects with history of radiation pneumonitis of grade 3 or above, regardless of recovered or not.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: low-dose radiation+CS1001
|
low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f; In the dose expansion part, more SCLC patients will be assigned. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the recommended radiation dose and preliminarily evaluate the anti-tumor efficacy of CS1001 in combination with low-dose radiotherapy in subjects with limited or extensive stage SCLC who failed the firstline treatment
Time Frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.
|
From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Adverse Events (AE) and Dose-Limiting Toxicity (DLT) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V4.03
Time Frame: From first dose to 30 days after last dose of CS1001, up to 2 years.
|
From first dose to 30 days after last dose of CS1001, up to 2 years.
|
Cmax: Peak concentration, the maximum drug concentration measured during one dosing cycle
Time Frame: From first dose to 30 days after last dose of CS1001, up to 2 years.
|
From first dose to 30 days after last dose of CS1001, up to 2 years.
|
The number and percentage of subjects with detectable Anti-drug Antibody (ADA)
Time Frame: From first dose to 30 days after last dose of CS1001, up to 2 years.
|
From first dose to 30 days after last dose of CS1001, up to 2 years.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: You Lu, MD, West China Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
- Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, Eder JP, Steele NL, Pieters A, Fairchild J, Antonia SJ. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019 Feb;14(2):237-244. doi: 10.1016/j.jtho.2018.10.003. Epub 2018 Oct 10.
- Li LY, Wang H, Chen X, Li WQ, Cui JW. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J (Engl). 2019 Dec 5;132(23):2790-2794. doi: 10.1097/CM9.0000000000000536.
- Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Ozguroglu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
- Yin L, Xue J, Li R, Zhou L, Deng L, Chen L, Zhang Y, Li Y, Zhang X, Xiu W, Tong R, Gong Y, Huang M, Xu Y, Zhu J, Yu M, Li M, Lan J, Wang J, Mo X, Wei Y, Niedermann G, Lu Y. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):212-224. doi: 10.1016/j.ijrobp.2020.05.002. Epub 2020 May 15.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 12, 2021
Primary Completion (Actual)
December 22, 2023
Study Completion (Actual)
December 22, 2023
Study Registration Dates
First Submitted
May 29, 2020
First Submitted That Met QC Criteria
June 5, 2020
First Posted (Actual)
June 9, 2020
Study Record Updates
Last Update Posted (Actual)
March 7, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS1001-101-13
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed Small Cell Lung Cancer
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
PharmaMarRecruitingRelapsed Small Cell Lung CancerUnited States, Spain, Korea, Republic of, United Kingdom, Israel, France, Taiwan, Germany, Australia, Belgium, Georgia, Italy, Switzerland, Denmark, Hungary, Poland, Japan, Romania, Canada, Brazil, Bulgaria, Austria, Chile, Turkey
-
AstraZenecaCompletedRefractory Solid Tumours | Relapsed Small Cell Lung Cancer (SCLC)United States, Canada
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers Squibb; MultiVir, Inc.TerminatedSmall Cell Lung Cancer | Lung Cancer | Relapsed Small Cell Lung CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers Squibb; Jazz PharmaceuticalsTerminatedSmall-cell Lung Cancer | Relapsed Small Cell Lung Cancer | Recurrent Small Cell Lung CancerUnited States
-
First People's Hospital of HangzhouRecruitingRelapsed Small Cell Lung Cancer | AnlotinibChina
-
AmgenActive, not recruitingRelapsed/Refractory Small Cell Lung CancerUnited States, Belgium, Italy, Spain, Portugal, Austria, Greece, Korea, Republic of, Denmark, Netherlands, Germany, France, Taiwan, Japan, United Kingdom, Poland, Switzerland, Singapore
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingRelapsed or Advanced Non-small Cell Lung Cancer
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingRelapsed or Metastatic Non-small Cell Lung CancerChina
-
Sierra Oncology, Inc.TerminatedRelapsed Metastatic KRAS-Mutated Non-Small Cell Lung CancerUnited States
Clinical Trials on CS1001
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCStone PharmaceuticalsRecruitingAdvanced Solid TumorChina
-
CStone PharmaceuticalsCompletedHodgkin LymphomaChina
-
CStone PharmaceuticalsCompletedExtranodal Natural Killer/T-Cell LymphomaUnited States, China
-
CStone PharmaceuticalsCompleted
-
CStone PharmaceuticalsCompleted
-
CStone PharmaceuticalsBayerCompletedAdvanced Refractory Solid TumorsAustralia
-
CStone PharmaceuticalsCompletedNon-Small Cell Lung Cancer Stage IIIChina
-
CStone PharmaceuticalsBlueprint Medicines CorporationCompletedHepatocellular CarcinomaChina
-
CStone PharmaceuticalsActive, not recruitingNon Small Cell Lung CancerChina
-
CStone PharmaceuticalsCompletedGastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaChina